Alessandro Andriani

A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma

Pellegrino Musto, Maria Teresa Petrucci, Tommasina Guglielmelli et al. · Cancer · 2008 · 186 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +12

Revised International Prognostic Scoring System (IPSS) Predicts Survival and Leukemic Evolution of Myelodysplastic Syndromes Significantly Better Than IPSS and WHO Prognostic Scoring System: Validation by the Gruppo Romano Mielodisplasie Italian Regional Database

Maria Teresa Voso, Susanna Fenu, Roberto Latagliata et al. · Journal of Clinical Oncology · 2013 · 137 citations · Full text

Medicine, Hematology, Internal Medicine +17

Symptomatic mucocutaneous toxicity of hydroxyurea in Philadelphia chromosome‐negative myeloproliferative neoplasms

Roberto Latagliata, Antonio Spadea, Michele Cedrone et al. · Cancer · 2011 · 48 citations · Full text

Medicine, Hematology, Pharmacology +16

Osteonecrosis of the Jaw in Patients with Multiple Myeloma Treated with Bisphosphonates: Definition and Management of the Risk Related to Zoledronic Acid

Anna Maria Cafro, Luciana Barbarano, Anna Maria Nosari et al. · Clinical Lymphoma & Myeloma · 2008 · 43 citations

Medicine, Oral Medicine, Bone Metabolism +14

Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients

Alessandro Andriani, Roberto Latagliata, Barbara Anaclerico et al. · American Journal of Hematology · 2016 · 38 citations · Full text

Medicine, Hematology, Internal Medicine +14